Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–1408. https://doi.org/10.1016/S1473-3099(16)30204-3

Article  PubMed  Google Scholar 

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545–558. https://doi.org/10.1016/S2468-1253(19)30119-0

Article  PubMed  PubMed Central  Google Scholar 

Shih YF, Liu CJ. Mother-to-infant transmission of hepatitis B virus: challenges and perspectives. Hepatol Int. 2017;11(6):481–484. https://doi.org/10.1007/s12072-017-9831-0

Article  PubMed  Google Scholar 

Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):811. https://doi.org/10.1186/s12879-019-4428-y

Article  PubMed  PubMed Central  Google Scholar 

Della Corte C, Nobili V, Comparcola D, Cainelli F, Vento S. Management of chronic hepatitis B in children: an unresolved issue. J Gastroenterol Hepatol. 2014;29(5):912–919. https://doi.org/10.1111/jgh.12550

Article  PubMed  Google Scholar 

Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis. 2002;186(3):295–301. https://doi.org/10.1086/341508

Article  PubMed  Google Scholar 

Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249–1262. https://doi.org/10.1016/j.jhep.2021.11.024

Article  CAS  PubMed  Google Scholar 

Cui F, Shen L, Li L, Wang H, Wang F, Bi S, et al. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy. China Emerg Infect Dis. 2017;23(5):765–772. https://doi.org/10.3201/eid2305.161477

Article  CAS  PubMed  Google Scholar 

Zhu S, Zhang H, Dong Y, Wang L, Xu Z, Liu W, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J Hepatol. 2018;68(6):1123–1128. https://doi.org/10.1016/j.jhep.2018.01.037

Article  CAS  PubMed  Google Scholar 

Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol. 2014;20(30):10395–10404. https://doi.org/10.3748/wjg.v20.i30.10395

Article  PubMed  PubMed Central  Google Scholar 

Vo Thi Diem H, Bourgois A, Bontems P, Goyens P, Buts JP, Nackers F, et al. Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr. 2005;40(2):141–145. https://doi.org/10.1097/00005176-200502000-00011

Article  PubMed  Google Scholar 

Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology. 1998;114(5):988–995. https://doi.org/10.1016/s0016-5085(98)70318-x

Article  CAS  PubMed  Google Scholar 

Zhu S, Dong Y, Wang L, Liu W, Zhao P. Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B. J Hepatol. 2019;71(5):871–875. https://doi.org/10.1016/j.jhep.2019.06.009

Article  CAS  PubMed  Google Scholar 

Li M, Li Q, Qu J, Yang H, Lv T, Kong Y, et al. The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2023;17(1):52–62. https://doi.org/10.1007/s12072-022-10415-7

Article  PubMed  Google Scholar 

Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002;346(22):1706–1713. https://doi.org/10.1056/NEJMoa012452

Article  CAS  PubMed  Google Scholar 

Jonas MM, Chang MH, Sokal E, Schwarz KB, Kelly D, Kim KM, et al. Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology. 2016;63(2):377–387. https://doi.org/10.1002/hep.28015

Article  CAS  PubMed  Google Scholar 

Rosenthal P, Ling SC, Belle SH, Murray KF, Rodriguez-Baez N, Schwarzenberg SJ, et al. Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection. Hepatology. 2019;69(6):2326–2337. https://doi.org/10.1002/hep.30312

Article  CAS  PubMed  Google Scholar 

Marrone A, Zampino R, Portella G, Grimaldi M, Durante-Mangoni E, Santarpia L, et al. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B. J Viral Hepat. 2005;12(2):186–191. https://doi.org/10.1111/j.1365-2893.2005.00619.x

Article  CAS  PubMed  Google Scholar 

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. https://doi.org/10.1007/s12072-015-9675-4

Article  CAS  PubMed  Google Scholar 

Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289–293. https://doi.org/10.1002/hep.510240201

Article  CAS  PubMed  Google Scholar 

Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virus infection in children and adolescents. World J Gastroenterol. 2021;27(36):6053–6063. https://doi.org/10.3748/wjg.v27.i36.6053

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Fan P, Xu Z, Dong Y, Wang F, Hong W, et al. Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase. J Clin Transl Hepatol. 2023;11(5):1011–1022. https://doi.org/10.14218/JCTH.2023.00014

Article  PubMed  PubMed Central  Google Scholar 

Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020;11(1):3410. https://doi.org/10.1038/s41467-020-17240-2

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Wang L, Zhong Y, Wong VW, Xu Z, Liu Y, et al. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J Clin Microbiol. 2010;48(12):4363–4369. https://doi.org/10.1128/JCM.01518-10

Article  PubMed  PubMed Central  Google Scholar 

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver D. Liver biopsy Hepatology. 2009;49(3):1017–1044. https://doi.org/10.1002/hep.22742

Article  PubMed  Google Scholar 

Jung KS, Park JY, Chon YE, Kim HS, Kang W, Kim BK, et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol. 2016;51(8):830–839. https://doi.org/10.1007/s00535-015-1153-1

Article  CAS  PubMed  Google Scholar 

Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325–1332. https://doi.org/10.1136/gutjnl-2013-305517

Article  CAS  PubMed  Google Scholar 

Cheng K, Chen Y, Wang X, Xu M, Liao W, Duan X, et al. Entecavir combined with interferon-alpha Is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Cancer. 2022;128(3):558–569. https://doi.org/10.1002/cncr.33949

Article  CAS  PubMed  Google Scholar 

Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, et al. Long-term benefits of interferon-alpha therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat. 2021;28(11):1554–1562. https://doi.org/10.1111/jvh.13598

Article  CAS  PubMed  Google Scholar 

Arnone OC, Serranti D, Bartolini E, Mastrangelo G, Stinco M, Trapani S, et al. Chronic hepatitis B in children, report of a single-centre longitudinal study on 152 children. J Viral Hepat. 2020;27(12):1344–1351. https://doi.org/10.1111/jvh.13382

Article  CAS  PubMed  Google Scholar 

Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int. 2020;14(2):212–224. https://doi.org/10.1007/s12072-020-10015-3

Article  PubMed  Google Scholar 

Zhu SS, Zeng QL, Dong Y, Xu ZQ, Wang LM, Chen DW, et al. Interferon-alpha plus ribavirin yields 98 % sustained virologic response in children aged 1–5 years with iatrogenic chronic hepatitis C. Hepatol Int. 2015;9(4):578–585. https://doi.org/10.1007/s12072-015-9671-8

Article  PubMed  Google Scholar 

Jonas MM, Balistreri W, Gonzalez-Peralta RP, Haber B, Lobritto S, Mohan P, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology. 2012;56(2):523–531. https://doi.org/10.1002/